Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by wildbird1


V.TLT

RE:About the addition of up to 9 CSS ...

Eoganacht nice article....In the link that you provided, a team of scientists...

March 19, 2023

V.TLT

313 millions shares outstanding...

Let's talk about TLT shares counts. As we speak almost all the heavy...

March 12, 2023

V.TLT

Ruvidar(TLD-1433) as an Adjuvant.

An Adjuvant treatment is a treatment that is given after an initial cancer...

February 26, 2023

V.TLT

RE:New McFarland Labs Research of TLD1433 Processes

CAinPLAP & BlueFranky... I am very far from being an expert on the...

February 25, 2023

V.TLT

RE:Dual chemo combo with great results

NOtaPOOp maybe you should learn to read... The 82 % in your article is for...

February 16, 2023

V.TLT

RE:" Missing 18 Pending patients data"

When I write a post, I always try to provide as much as possible the source...

February 13, 2023

V.TLT

RE:RE:RE:" Missing 18 Pending patients data"

CancerSlayer, thank's for your response, I like it when somebody take the...

February 12, 2023

V.TLT

" Missing 18 Pending patients data"

Like almost everybody on this board, I have always thought that the 12...

February 12, 2023

V.TLT

The next CR% data???

What can we expect when the next set of CR% data will be released. 1) We...

February 5, 2023

V.TLT

RE:Feature article about Theralase on biotuesdays.com website

It does seem that this Jan 3,2023 article was written as a reminder of what...

January 15, 2023

V.TLT

RE:Feature article about Theralase on biotuesdays.com website

Eoganacht...Great  Article. I like the part were TLT said. "...

January 8, 2023

V.TLT

RE:RE:Has to be over 60%CR...

enriquesuave wrote: After that press release , they no longer used the 67...

December 30, 2022

V.TLT

Vaccine & therapeutic...

Before we go on the holidays break, here is a little remender for the...

December 23, 2022

V.TLT

Has to be over 60%CR...

I am one of the very few people on this board that come up with a CR% over 60...

December 21, 2022

V.TLT

RE:RE:RE:RE:RE:RE:NSCLC and GBM indications

Good post Eoganacht... Here is a quote that you can find in almost every...

December 19, 2022

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:Is FDA submission material enough for an NR?

StevenBirch, here is a quote from the FDA site , as a complement to your post...

December 16, 2022

V.TLT

RE:Optimized group efficacy % @90-days: CR=65%, PR=10%, TR=75%

ScienceFirst, after reading your post and Eoganacht post, I decided to give...

December 12, 2022

V.TLT

BTD...Vaccine... Competition.

BTD timeline. In the last PressRelease TLT said " Completion of the 450...

December 4, 2022

V.TLT

Progressing in the right direction.

TLT is progressing in the right direction and nobody can contredic that fact....

December 1, 2022

V.TLT

RE:RE:N-803 had been granted Breakthrough designation. We will too

ScienceFirst great catch...(the best catch I have seen lately). If we sum-up...

November 27, 2022

Featured Company